Seeking Late Preclinical Oncology Assets: Small Molecules with IND-enabling Data and Patient Stratification Potential

Cumulus Oncology is seeking small molecule oncology assets that are at or near the IND-enabling stage and supported by GLP toxicology data, a defined biomarker strategy, and has potentially started GMP synthesis. In particular, their goal is to identify programs with strong translational relevance and a clear path to early clinical proof of concept.

Approaches of Interest:

• Ideal assets will have a well-characterized mechanism of action and potential for monotherapy or rational combinations
• Assets with defined biomarkers to support patient selection will...